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Summary. Despite our deep understanding of
neuroblastic tumors, some patients still suffer treatment
failure, so pre-treatment risk stratification still requires
improvement and the search for new therapeutic targets
must continue. Here we correlated prognostic clinical
and biological features of neuroblastic tumors with the
density of extracellular matrix glycosaminoglycans (the
main components of the extracellular matrix ‘ground
substance’), in nearly 400 primary samples. We also
studied the relationship between the density of
extracellular matrix glycosaminoglycans and the
expression of B3GALT6, an enzyme required for their
synthesis. We associated a decrease in glyco-
saminoglycans with neuroblastomas that were
histopathologically poorly-differentiated or undif-
ferentiated, as well as with metastatic disease, and 1p36
deleted tumors. This decrease in glycosaminoglycans
was also related to abnormal nuclear B3GALT6
expression in neuroblastic cells. These findings point
towards the importance of the ground substance in the
aggressiveness of neuroblastic tumors, which should
therefore be considered when developing novel therapies
for treating neuroblastomas. 
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Introduction
Glycosaminoglycans (GAGs) constitute the main
components of the fundamental or the ground substance
of the extracellular matrix (ECM) and can be found as
free GAGs or, especially, forming proteoglycans
(Noguera et al., 2012). GAGs have unique biofiltering
and cell-anchoring properties and are considered to be
essential in several biological processes by regulating
the main cellular functions (Afratis et al., 2012).
Additionally, they have been related to various
malignancies and are, therefore, considered to be key
players both in cancer cell biology and as novel
therapeutic agents (Afratis et al., 2012). The GAG
content is affected differently in several malignancies
(Bharadwaj et al., 2009; Sironen et al., 2011; Weyers et
al., 2012). GAGs usually increase by approximately 15%
in aggressive breast cancers compared to non-lethal
presentations (Weyers et al., 2012). One particular GAG,
hyaluronic acid (HA), accumulates in the stroma of
human adenocarcinomas, and other human tumors, and
modulates the intracellular signaling pathways, cell
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proliferation, motility, and invasive properties of
malignant cells (Tammi et al., 2008). 
HA is also related to several key biological processes
such as host-tumor interactions, vascular and lymphatic
angiogenesis, epithelial-mesenchymal transition and, in
some adult cancers such as glioma, pancreatic, breast,
and prostate cancer, it is related to local and distant
metastases (Sironen et al., 2011). Notwithstanding,
squamous cell carcinomas and malignant melanomas
tend to have a reduced HA content (Bharadwaj et al.,
2009). Other studies have found a link between GAG
under-sulfation or overexpression of chondroitin sulfate
(CS) and poor prognosis in prostate cancer (Ricciardelli
et al., 2009; Weyers et al., 2012). GAGs are linked to
core proteins and form proteoglycans through a
tetrasaccharide linkage region which is synthesized in all
secretory cell Golgi complexes (Victor et al., 2009;
Vigetti et al., 2014). With the exception of HA, this
linkage region is required for GAG biosynthesis, and is
catalyzed by four enzymes, which include
galactosyltransferase 2, also known as β-3
galactosyltransferase or B3GALT6 (Bai et al., 2001;
Hennet, 2002). Of note, defective B3GALT6 has
recently been related to skeletal and connective tissue
disorders (Malfait et al., 2013; Nakajima et al., 2013; Xu
et al., 2014).
Neuroblastic tumors (NBTs) comprise a variety of
entities and are a pediatric disease responsible for 15%
of childhood deaths from cancer (Kaatsch, 2010).
Patients with NBTs present a wide range of clinical
evolutions which may result in rapid and aggressive
metastatic dissemination or, on the contrary, spontaneous
regression (Cohn et al., 2009). Although a recent and
well-defined pre-treatment risk classification scheme is
now playing a central role in improving survival, more
effort must still be made to improve patient survival,
both in general and specifically in the high-risk patient
subgroup (Pinto et al., 2015). 
Recently, Knelson and colleagues (2014)
demonstrated that ECM GAGs, especially heparin
sulfate (HS), participate in different cellular processes,
such as neuroblastic differentiation and cellular
progression. Therefore, here we investigated whether
the abundance of GAGs was related to prognosis and to
metastatic processes in NBT, with the aim of using this
as a factor to enhance pre-treatment risk stratification
of this disease. We also investigated whether GAGs
could be understood as ‘cancer attractors’ or
‘hyperstructures’ of therapeutic interest in NBT (Huang
et al. ,  2009). For this purpose, we used digital
pathology to quantify GAGs in primary NBT samples,
and performed statistical analyses to correlate their
density to the International Neuroblastoma Risk Group
(INRG) features that have known prognostic value
(Cohn et al., 2009) and to other frequent genetic
aberrations, in order to determine whether any
differences in the ground substance density in NBT and




We analyzed 19 tissue microarrays (TMAs)
containing at least two representative 1-mm cylinders
taken from 387 primary tumors. All the samples were
referred to the Spanish Reference Centre for NBT
Biological and Pathological studies (Department of
Pathology, University of Valencia-INCLIVA) and had
been obtained between 1996 and 2007.
International neuroblastoma risk group biological and
clinical data
Paraffin sections were stained with hematoxylin and
eosin, underwent immunohistochemistry, and were
examined by a pathologist in order to histopathologically
categorize NBT following the International
Neuroblastoma Pathology Classification (INPC) into:
ganglioneuroma (GN), intermixed ganglioneuroblastoma
(iGNB), and neuroblastoma (NB) categories, followed
by the NB subdivisions: differentiating NB (dNB),
poorly-differentiated NB (pdNB), and undifferentiated
NB (uNB) (Shimada et al., 1999). GN and iGNB are
stroma-rich/stroma-dominant tumors, whereas NBs are
stroma-poor tumors; nodular GNBs present mainly
stroma-rich areas with nodules of d, pd, and u NB. We
considered these tumors to correspond to the NB in the
nodular area-the area included in the TMAs.
Fluorescence in situ hybridization (FISH) and single-
nucleotide polymorphism arrays (SNPa) were performed
to assess the genetic changes which the INRG considers
to be independent risk factors, such as the status of the
MYCN oncogene (amplified or non-amplified) and the
11q23 region (deleted or non-deleted), as well as the
presence of the frequently altered 1p36 region (deleted
or non-deleted) and 17q chromosome arm (gained or
non-gained), following previously published European
guidelines (Ambros et al., 2003, 2009; Piqueras et al.,
2011; Villamon et al., 2013). 
Following the INRG classification scheme, all these
variables, along with the stage (localized 1 and 2,
metastatic special, and metastatic) and patient age (<18
months or ≥18 months)-information provided by the
attending pediatric oncologists or the NBT clinical
studies reference center-were used to define the patient
risk group (very low, low, intermediate, or high), assign
an appropriate probable survival rate, and provide proper
treatment (Cohn et al., 2009). The number of samples in
each group is shown in Table 1. The different
pretreatment risk groups and the 1p36 status, were
related to event-free survival as shown in Fig. 1. Patients
with high-risk NBT disease and 1p36 deletion had an
increased risk of relapse compared to those with lower-




For the whole set of samples (from 387 primary
tumors), one 3-µm section of each TMA was cut and
stained with an Alcian blue pH 2.5 stain kit (Artisan™,
Dako) that stains acidic GAGs such as heparan sulfate,
dermatan sulfate (HS), CS, and HA, as well as
sulfomucins and sialomucins. The density of GAGs was
evaluated using image analysis. Immunohistochemistry
with anti-B3GALT6 antibody (Abcam ab103375, 1/100),
which is physiologically found in the Golgi complex of
these cells (Fig. 2), was performed in a subset of 25
samples (18 with 1p36 deletion and 7 with non-deleted
1p36), following the protocol recommended in the
datasheet. Expression of the B3GALT6 enzyme by
stromal and tumoral cells was assessed and agreed upon
by two researchers and was quantified as the percentage
of cells of each type expressing the protein in the Golgi
complex; we also considered other possible locations for
this enzyme.
Image analysis
All TMA slides were scanned with an Aperio XT
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Table 1. Clinical and biological variables related with the density of glycosaminoglycans.
Variable Number of cases GAG density (median) Mean ± Standard deviation (minimum-maximum) Statistical test p-values
Risk group
High 87 2.10 3.31±4.22 (0.19-32.46)
0.023** (−0.115) 
(HR vs. IR vs. LR vs. VLR)
Intermediate 29 3.00* 3.97±3.91 (0.31-17.71)
Low 69 2.85 4.34±4.50 (0.14-20.63)
Very low 164 3.18 4.07±3.80 (0.37-31.03)
Stage
M 89 2.43 3.54±4.28 (0.14-32.46) 0.000** (−0.282) 
(L1 vs. L2 vs. Ms vs. M) 
0.000** (L1+L2 vs. Ms+M)
Ms 26 1.94* 2.83±1.94 (0.49-8.79)
L2 122 2.58 4.11±4.09 (0.30-20.63)
L1 130 3.22 4.29±4.13 (0.37-31.03)
Age
≥18 months 147 2.90* 4.30±4.82 (0.19-32.46) 0.466<18 months 223 2.70 3.75±3.55 (0.14-20.36)
Histopathology (Mean % Schwannian cells)
uNB (26.92) 44 2.25 3.78±5.14 (0.30-32.46) 0.000** (dNB+pdNB+uNB 
versus GN+iGNB) 
0.007** (−0.153) 
(dNB vs. pdNB vs. uNB)
pdNB (28.72) 232 2.48 3.45±3.81 (0.14-30.19)
dNB (32.36) 36 3.24 3.81±2.40 (0.70-11.89)
iGNB (59.20) 25 4.54 5.72±5.61 (1.28-31.03)
GN (81.75) 17 6.50 7.83±4.57 (2.49-19.42)
MYCN
Amplified 49 2.21 3.23±3.15 (0.30-14.27) 0.060^Non-Amplified 337 2.88 4.24±4.52 (0.14-32.46)
11q
Deleted 61 2.92 3.73±3.52 (0.14-15.78) 0.391Non-deleted 288 2.84 4.24±4.52 (0.30-32.46)
1p36~
Deleted 118 2.43 3.30±3.14 (0.19-19.42) 0.017**Non-deleted 262 2.93 4.48±4.83(0.14-32.46)
17q~
Gained 157 2.71 3.51±3.07 (0.14-17.99) 0.180Non-gained 202 2.84 4.63±5.27 (0.32-32.46)
Statistical test p-values: the p-values, coefficient and the variables used for Spearman’s rank correlation are indicated in bold font. The rest of the
prognostic parameters were analyzed by the Mann-Whitney test; these p-values and variables are also indicated. The categories of the variables are
presented from least favorable to most favorable. Abbreviations: GAGs, glycosaminoglycans; VLR, very low risk; LR, low risk; IR, intermediate risk; HR,
high risk; M, metastatic; Ms, metastatic special; L, localized; uNB, undifferentiated neuroblastoma; pdNB, poorly differentiated neuroblastoma; dNB,
differentiating neuroblastoma; iGNB, intermixed ganglioneuroblastoma; GN, ganglioneuroma; ~denotes frequent genetic changes not considered to
define the international NB risk group; ^ denotes that the p-value not statistically significant, but is near the level of significance; ** represent statistically
significant differences; * Does not follow the order of decreasing malignancy.
whole-slide scanner (Leica Biosystems, Wetzlar,
Germany) at 40× magnification. Each cylinder was
analyzed individually with the Aperio Positive Pixel
Count Algorithm using Aperio ImageScope software
(Leica Biosystems, Wetzlar, Germany). This algorithm
counted the number of pixels belonging to a given
staining intensity. The intensity of each pixel was the
average between the values of red, green, and blue
(RGB) intensities. The algorithm was used with the
default parameters except for the RGB intensity of the
Alcian blue-stained pixels which ranged from 221 to
255. The number of Alcian blue-stained pixels was
multiplied by the area of a single pixel (0.25×0.25
µm/pixel, based on the image resolution) to obtain the
total Alcian blue-stained area per cylinder. Additionally,
the outline of each cylinder was carefully selected in
order to measure the area of analysis, and from that, the
percentage (%) of Alcian blue-stained area per cylinder;
i.e., the GAG density was calculated as the area positive
for Alcian blue divided by the total area of the cylinder,
multiplied by 100. The density of GAGs per patient
sample was calculated using the mean density of the
GAGs in all the cylinders from the same patient. Thick
fibrous trabeculae were excluded from the analysis.
Artefacts, scant material, and lost cylinders were
considered as non-evaluable.
Statistical methods
The continuous numerical variable derived from the
morphometric analysis did not follow a normal
distribution and was therefore correlated to the
prognostic INRG categories using the non-parametric
Mann-Whitney U test for dichotomized variables and
Spearman’s rank correlation coefficient for risk, stage,
and differentiation-grade variables. A significance level
of 95% was established.
Results
Glycosaminoglycans and international neuroblastoma
risk group classifications
In general, there were very few GAGs in the ECM
of the NBT samples, with a mean density of 4.11±4.37%
and a median of 2.82% of the tissue area; the minimum
value was 0.14% and the maximum was 32.46% and the
median GAG densities and statistical comparisons
related to the INRG clinical and biological variables are
shown in Table 1. The tumor ECM from patients in the
high-risk group usually presented a lower density of
GAGs compared to that from non-high risk patients
(2.10 vs. 2.75%, respectively). A lower density of GAGs
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Fig. 1. Kaplan-Meier survival curves with event-free survival in the patients included in the study. A. International neuroblastoma risk-group (INRG) pre-
treatment stratification. B. 1p36 status; the average survival times are shown.
was found in NB samples with respect to GN and iGNB
samples, and within the NB subset the GAG density was
proportionally lower in more undifferentiated NB
samples. Both the metastatic stage (M) and the special
metastatic stage (Ms), which is related to a better
prognosis but greater spreading of the disease compared
to the M stage, were associated with the lowest densities
of GAGs (2.43% and 1.94%, respectively). The ECM
from M or Ms-stage tumors presented significantly
fewer GAGs compared with the L1 and L2stages
(P=0.000). Finally, the GAG density was significantly
lower in samples with 1p36 deletions compared to their
non-deleted counterparts (P=0.017). As an illustrative
example, the relationship between the histopathology,
1p36 deletion status, and density of GAGs is shown for
four cases in Fig. 3.
Glycosaminoglycans and B3GALT6 expression
In the subset of samples that were immunohisto-
chemically studied, B3GALT6 enzyme immunostaining
was observed with a perinuclear arrangement in the
Golgi complex of Schwann cells in all the samples, in an
average 65.2±28.5% cells each (range: 5-95%).
Additionally, tumor cells also expressed this enzyme in
80% of the samples, with a mean 12.8±15.4% positive
cells each (range: 5-60%). In 46% of the samples, with a
mean 27.7±34.5% positive neuroblasts (range: 10-95%),
the B3GALT6 enzyme was found in an abnormal
subcellular location in the nuclei of tumoral cells. Within
the samples with the 1p36 deletion, Golgi complex
B3GALT6 enzyme expression was seen in more stromal
cells but fewer tumor cells in samples with a low density
of GAGs (13 out of 18; 72.2%) compared to samples
with higher densities of GAGs (stromal cells: 64.6% vs.
52.0%; tumoral cells: 12.9% vs. 20.0%, respectively).
Only the samples with very few GAGs presented nuclear
B3GALT6 enzyme accumulation (mean 36.9% of
positive neuroblasts). The relationship between the
density of GAGs, 1p36 deletion, and B3GALT6 enzyme
expression, is explained in Fig. 3 for two cases. 
Discussion
In general, we found that the ECM in NBTs contains
scant GAGs, which is similar to the stroma of the
sympathetic trunk ganglia and the adrenal medulla
where these tumors originate. Nevertheless, by analyzing
a large cohort of NBT samples by digital pathology, we
demonstrated that the low levels of ECM ground
substance in these samples is associated with
undifferentiated states, metastasis, and 1p36 deletions. In
this study, these factors were strongly associated with
poor prognosis in NBT patients. Several studies have
recently demonstrated the potential of using GAGs as
therapeutic targets. For instance, Heymann and
colleagues (2016) designed over-sulfated GAGs and
found that they inhibited migration and invasiveness in
vitro in human and murine osteosarcoma cell lines.
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Fig. 2. Expression of the B3GALT6 enzyme in control samples. 
A. Human parotid gland with high perinuclear B3GALT6 expression in
the Golgi complex of the cells of acini (A) and ducts (D) as well as
positive staining in the endothelial cells of a blood vessel (BV). All these
cell types are known for their increased glycosaminoglycan synthesis.
B. Hepatocytes which are not synthesizing glycosaminoglycans and are
neagative for B3GALT6 enzyme staining. C. Neuroblastic tumor with
intact (non-deleted) 1p, showing perinuclear B3GALT6 expression in the
Golgi complexes of stromal and neuroblastic cells (approximately 80%
and 60% positive cells, respectively).
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Fig. 3. Relationship between histopathology, glycosaminoglycans (GAGs), 1p36 status, and B3GALT6 enzyme expression in neuroblastic tumors
(NBTs). A red line highlights microscopic images and schematic representations of stroma-dominant/rich and stroma-poor NBTs with 1p36 deletion
(1pD). A. Microscopic images of stroma-dominant/rich and stroma-poor NBTs stained with Alcian blue (GAGs in blue); 1p36 status and GAG densities
are indicated. Inserts: mark-up images with GAGs in blue and neuroblastic and stromal cells in orange. B. Detection of 1pD and related GAG synthesis.
Fluorescence in situ hybridization (FISH; touch preparation), using the chromosome 1 centromere (SE1, in red) and 1p telomere probes (1p36, in
green), shows nuclei with 1pD (2:1). Chromosome 1 profile derived from a single nucleotide polymorphism array (SNPa) showing deletion of the 1p
arm. Schema representing the hypothetical relationship between 1pD, B3GALT6 gene loss, inhibition of functional B3GALT6 enzyme expression, and a
decrease in GAG synthesis. C. Schemas of the different NBT histopathologies with 1p36 non-deleted nuclei (1pND, in green) and 1pD nuclei (in
orange). In the 1pND samples, cells would be able to synthesize the B3GALT6 enzyme and GAG density would be dependent on the number of
Schwann cells, neuroblasts, and other extracellular matrix elements. In the 1pD samples, the stromal cells would mainly be those synthesizing the
functional B3GALT6 enzyme, therefore, the GAG density would be higher for the dominant/rich sample and lower for the stroma-poor sample, which
will always be lower than their non-deleted counterparts. D. Immunostaining of the B3GALT6 enzyme in 1pD samples. Those with a higher density of
GAGs (stroma-dominant/rich NBTs) have fewer Schwann cells (SCs+) and more neuroblasts (Nbs+) expressing the B3GALT6 enzyme in the Golgi
complex, and show normal B3GALT6 expression in Nbs compared with their stroma-poor NBT counterparts. Only the samples with a lower density of
GAGs present abnormal nuclear B3GALT6 enzyme expression.
Thus, we hope that the use of derivative GAG molecules
(Pomin, 2015) or the induction of GAG synthesis by
restoring the B3GALT6 gene via nanotechnologies, may
be able to inhibit metastatic processes in NB. Therefore,
we suggest that GAGs should be considered as targets in
NBT.
A low density of glycosaminoglycans is associated with
undifferentiated neuroblastoma
Recent studies have demonstrated that ECM GAGs
enhance the differentiation of some cell types (Akita et
al., 2004) and specifically, HS participates in
neuroblastic differentiation, thus suppressing
neuroblastoma growth (Knelson et al., 2014). Increased
densities of ECM GAGs promotes neuroblastic cell
binding to their matrix and, in vitro, they settle into this
substrate and differentiate (Knelson et al., 2014). In our
cohort, the NBT cell differentiation status was inversely
related with the density ECM GAGs. In addition, we
also found that the quantity of GAGs per tumor sample
strongly depended on the abundance of Schwannian
stroma (Table 1) which is, in turn, directly related to the
INPC NBT histological category-GN, GNB, or NB
(Shimada et al., 1999). Furthermore, the NB
differentiation grade negatively correlated with GAG
density such that low GAG density was associated with
lower levels of neuroblastic differentiation (dNB vs. NB
vs. uNB, P=0.007).
Low levels of glycosaminoglycans are related to
extracellular matrix stiffness and disseminated disease in
neuroblastic tumors
HS proteoglycan chains are involved in ECM
organization by binding other ECM molecules such as
collagens, and their absence promotes invasion and
migration in malignant cells (Sanderson, 2001). High
ECM HA content is associated with a poor prognosis in
breast, lung, and ovarian adenocarcinomas but a good
prognosis in squamous cell carcinoma and melanoma
(Anttila et al., 2000; Karjalainen et al., 2000; Kosunen et
al., 2004); in the latter two, low ECM HA content is also
directly correlated with metastatic potential (Karjalainen
et al., 2000; Kosunen et al., 2004). Similarly, the
overexpression of lumican, another common
proteoglycan, favors human colon cancer cell migration
by causing filamentous actin reorganization and inhibits
melanoma cell migration which is dependent on integrin
binding (Radwanska et al., 2012; Pietraszek et al., 2013). 
Our group previously described a relationship
between fibrous ECM scaffold stiffening and NBT
malignancy, whereby abnormal collagen type III or
reticulin fiber network organization and increased
crosslinking augmented ECM stiffness and porosity
(Tadeo et al., 2017), which has been shown to enable
tumor cell migration (Seewaldt, 2014). In this current
study, the NBT samples with the lowest GAG densities
corresponded to metastatic disease stages M and Ms.
According to our previous work, the reduced number of
GAGs in these tumors favors the occurrence of a rigid
ECM scaffolding and, thus, tumor cell migration. Hence,
the lower density of GAGs in M-stage tumors in this
cohort may have resulted from the increased presence of
fibers or cell components in these cells, which would
limit the physical space available for GAGs (Tadeo et
al., 2017). 
The extracellular matrix glycosaminoglycan density is
related to neuroblastic cell genetics
To understand the relationship between the 1p36
deletion and the reduced number of GAGs found in our
cohort samples, one must understand proteoglycan
biosynthesis. A tetrasaccharide linkage region is
required for the biosynthesis of all GAGs except for
HA, which is catalyzed by three enzymes, including
B3GALT6 (Bai et al., 2001; Hennet, 2002). The
B3GALT6 gene is located in the 1p36.33 region and so,
abnormal or altered linkage-region synthesis and
thereby, also GAG synthesis (except for HA), would be
expected if this region is deleted. In line with this, a
series of B3GALT6 mutations was associated with GAG
scarcity (Nakajima et al., 2013). Deletions in 1p in
NBTs usually include the 1p36.33 region and usually
occur in heterozygotes (White et al., 2005; Berbegall et
al., 2016). In this study, samples with a low GAG
density usually also harbored the 1p36 deletion and
presented low B3GALT6 enzyme expression in the
Golgi complex as well as abnormal accumulation of this
enzyme in the tumoral nuclei. Together, this evidence
suggests that the B3GALT6 enzyme produced may not
function normally. On the contrary, higher densities of
GAGs in samples with the 1p36 deletion may be
explained by the presence of varying numbers of
Schwann cells where regulated B3GALT6 enzyme
production and GAG synthesis would continue to some
degree. In addition, alternative pathways for GAG
synthesis, which skip the B3GALT6 enzymatic
polymerization step and could explain this
phenomenon, have also been suggested (Nakajima et
al., 2013).
Conclusions
Neuroblastic cells with 1p36 deletion and scant
ECM GAG underexpress B3GALT6 in the Golgi
complex and exhibit abnormal nuclear expression of
this enzyme. Consequently, the low density of GAGs in
the ECM presumably produced by these changes may
contribute to a lack of neuroblastic differentiation and
its spread. Thus, because of their strong correlation with
some of the variables determining the risk of
progression, GAGs and their interacting elements could
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